Preliminary results following the use of a fixed combination of timolol-brimonidine in patients with ocular hypertension and primary open-angle glaucoma

Clinical Ophthalmology

Volumn 3, Issue 1, 2009, Pages 227-230

  Papaconstantinou, Dimitris ^a   Georgalas, Ilias ^b   Kourtis, Nikolaos ^a   Pitsas, Christos ^a   Karmiris, Efthimios ^a   Koutsandrea, Chrysanthi ^a   Ladas, Ioannis ^a   Georgopoulos, Gerasimos ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b G GENNIMATAS GENERAL HOSPITAL   (Greece)

Author keywords

Fixed combination 0.2 brimonidine 0.5 timolol; Ocular hypertension; Primary open angle glaucoma

Indexed keywords

BIMATOPROST; BRIMONIDINE PLUS TIMOLOL; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; LATANOPROST PLUS TIMOLOL; TRAVOPROST;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BLURRED VISION; CLINICAL ARTICLE; CLINICAL FEATURE; CONJUNCTIVA DISEASE; CORNEA DISEASE; CORNEA INJURY; DRUG EFFICACY; DRUG MECHANISM; DRUG WITHDRAWAL; FEMALE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; MALE; OPEN ANGLE GLAUCOMA; PROSPECTIVE STUDY; UNSPECIFIED SIDE EFFECT;

EID: 77953366647     PISSN: 11775467     EISSN: 11775483     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Nouri-Mahdavi K, Hoffman D, Coleman AL, et al; Advanced Glaucoma Intervention Study. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology. 2004;111:1627-1635.
2. Bengtsson B, Leske MC, Hyman L, Heijl A; Early Manifest Glaucoma Trial Group. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology. 2007;114:205-209.
3. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M; Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268-1279.
4. Gordon MO, Beiser JA, Brandt JD, et al. The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:714-720.
5. Sherwood MB, Craven ER, Chou C, DuBiner HB, Batoosingh AL, Schiffman RM, Whitcup SM. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension: a 12-month randomized trial. Arch Ophthalmol. 2006;124:1230-1238.
6. Goñi FJ; Brimonidine/Timolol Fixed Combination Study Group. 12-week study comparing the fixed combination of brimonidine and timolol with concomitant use of the individual components in patients with glaucoma and ocular hypertension. Eur J Ophthalmol. 2005; 15:581-590.
7. Craven ER, Walters TR, Williams R, Chou C, Cheetham JK, Schiffman R; Combigan Study Group. Brimonidine and timolol fixed-combination therapy versus monotherapy: a 3-month randomized trial in patients with glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2005; 21:337-348.
8. Konstas AG, Katsimpris IE, Kaltsos K, et al. Twenty-four-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components. Eye. 2008;22:1391-1397.
9. Arcieri ES, Arcieri RS, Pereira AC, Andreo EG, Finotti IG, Sá Filho WF. Comparing the fixed combination brimonidine-timolol versus fixed combination dorzolamide-timolol in patients with elevated intraocular pressure. Curr Med Res Opin. 2007;23:683-689.
10. Frampton JE. Topical brimonidine 0.2%/timolol 0.5% ophthalmic solution: in glaucoma and ocular hypertension. Drugs Aging. 2006;23:753-761.
11. Alvarado JA. Reduced ocular allergy with fixed-combination 0.2% brimonidine-0.5% timolol. Arch Ophthalmol. 2007;125:717.